Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC Ltd : World’s leading Event Organizer

Conference Series LLC Ltd Conferences gaining more Readers and Visitors

Conference Series LLC Ltd Web Metrics at a Glance

  • 3000+ Global Events
  • 25 Million+ Visitors
  • 25000+ unique visitors per conference
  • 70000+ page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Renowned Speakers

Steinar Madsen

Steinar Madsen

Medical Director
Norwegian Medicines Agency

Eleonora Babayants

Eleonora Babayants

Galaxy Consulting

Steven J. Durham

Steven J. Durham

Partner Labaton Sucharow USA

Kouros Motamed

Kouros Motamed

Drug Development
NantBioscience Inc

Michael D Winther

Michael D Winther

Associate Director
Genome Institute of Singapore

Ruben Boado

Ruben Boado

Vice President & Cofounder-ArmaGen

Mandla Stanley Makhanya

Mandla Stanley Makhanya

Vice Chancellor
University of South Africa
South Africa

William R Strohl

William R Strohl

BiStro Biotech Consulting

Biobetters 2018

About Us

Conference Series LLC Ltd, Scientific Event Organizer and the World Class Open Access Publisher, announcing its International Conference on Biobetters and Regulatory Affairs during June 27-28, 2018 at Vancouver Canada . This interesting event is managed in such a way to provide an exclusive platform for educators, new researchers, and learners to present and discuss the most recent innovations, possibilities, and concerns adopted in the field. Biobetters- 2018 will comprise an informative and exciting conference program including leading keynote speakers, poster presenters, session speakers who will be presenting their research on the topics related .

Biobetters are improved versions of originator biologics. Although there are varying interpretations of the term biobetter, according to Andrew Merron, therapy lead in oncology and biosimilars at healthcare research and consulting company Decision Resources Group, the improvements in these products often lie in efficacy, safety, or delivery.

Therefore to acquire all this knowledge we invite you heartedly to join us at the Biobetters-2018, where you will be sure to have a great experience with experts from around the world. All the important members of Biobetters -2018 organizing committee look further to meet you at Vancouver, Canada.

Confirmed Keynote Forum

Mayor Message

Scientific Sessions

Conference Series LLC Ltd organizes 1000+ Conferences every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Following the success of previous Advanced Clinical Research and Clinical Trails  held on  September 20-21, 2017 Dublin, Ireland,  7th International Conference and Exhibition on Pharmaceutical Regulatory Affairs and IPR  September 25-26, 2017, Chicago, Illinois, USA , 11th European Biosimilars Congress, on April 26-27, 2018 Rome, Italy.

We are now delighted Announce International Conference on Biobetters and Regulatory Affairs  from 27-28, 2018 in Vancouver Canada. Conferences have been designed in an interdisciplinary manner with a multitude of tracks to choose from every segment and provides you with a unique opportunity to meet up with peers from both industries belonging to Biotech and Pharmaceuticals sectors and academia.

We cordially invite all concerned people from different countries of Europe (UK, London, Spain, Istanbul, Denmark, Netherlands, Germany, France, Italy, Brazil, Turkey, Israel, India, China, Japan) to come join us at our event and make it successful by your participation.

Scientific Sessions


The term Biobetter refers to a recombinant protein drug that is in the same class as an existing biopharmaceutical but is not identical; it is improved over the original. Biobetters build on the success of existing, approved biologics but are considered less of a commercial risk than developing a brand new class of biologic.

Biobetters are not entirely new drugs and they aren't genericversions of drugs, either.While many consider Biosimilars to be generic versions of biotech drugs, it isn't possible to create a generic biologic drug. That's because biopharmaceuticals are produced in living organisms - such as animals or bacteria - and cannot be copied exactly.

1. Building Biobetters : The regulatory landscape

Regardless of whether new forms of presently promoted, or again organic medications, biobetters are items particularly intended to amplify clinical execution. Execution advancement may incorporate, among different upgrades, improved focusing on and conveyance, expanded action and half-life, and diminished immunogenicity. Along these lines, it is important that such items are created productively and rapidly, to permit patients access to drugs that give greatest clinical advantages.

2.The structure of proteins

Progressively, sedate engineers are looking to vast atoms and especially proteins as a restorative choice. Definition of a protein tranquilize item can be a significant test, however without a decent comprehension of the idea of protein structure and the conformational qualities of the particular protein being planned, the outcomes can be ruinous. This specialized brief expects to give the peruser a brisk outline of protein structure

3.Biosimilar Development: Principles and Pitfalls

Making a biosimilar requires gifted researchers to lead ventures in a lab that require an abnormal state of accuracy. Advanced scientific instruments and strategies are utilized to contrast the biosimilar with the reference item on the fine subtle elements of the particle. Much of the time, a hearty expository information bundle is inadequate for endorsement without non– clinical and clinical information. The explanatory information with the non– clinical and clinical information together contain the "totality of confirmation" for which the level of similitude can be surveyed

4.Opportunities & Challenges from a Market

Creating and assembling biosimilars is testing, so entrenched biopharmaceutical organizations are putting resources into these vital pharmaceuticals.

Biologics are among the most noteworthy cost medications on the worldwide market today, which suggests the requirement for minimal effort choices. In developing markets, biosimilars officially offer more reasonable costs, which are alluring, as well as basic to economies where costly medications are not fiscally possible

5.Regulatory Essentials

Regulatory Affairs is an incredible vocation for experts who wish to work in a challenging and dynamic field that is at the focal point of science, business, government and above all, sparing individuals' lives. The Regulatory Essentials, give professionals an extensive and balanced education concentrating on the key areas of Regulatory Affairs and the FDA  imposed regulations pertinent to the pharmaceutical and biologics industry.

6.Regulatory Strategy Forum for Medical Devices

Knowing how to develop an effective global regulatory strategy is an essential skill for regulatory professionals. Successful global regulatory strategies maximize commercial opportunities for healthcare product manufacturers while minimizing company risk. By engaging in in-depth analysis and workgroup collaboration, you will gain a thorough understanding of ways to enhance your strategy and further your product’s succe

7.Regional Regulatory Update Of  US &EU

Regulatory update actively monitors and analyzes  regulatory changes in countries worldwide, helping them to ensure compliance on an on-going basis and enabling them to easily roll out regulatory reporting operations into multiple branches, as well as reducing total cost of ownership and maintenance once the system is fully configured.

8.Regional Regulatory Update of GCC, ASIA AND AFRICA

Regulatory updates seeks to facilitate the harmonisation of regulatory policies, legislation, standards and practices and to be a platform for effective cooperation

To Collaborate Scientific Professionals around the World

Conference Date June 27-28, 2018

For Sponsors & Exhibitors

Speaker Opportunity

Day 1 Day 2

Supported By

International Journal of Drug Development and Research

Journal of Bioequivalence & Bioavailability

Journal of Bioanalysis & Biomedicine

Pharmaceutical Regulatory Affairs: Open Access

All accepted abstracts will be published in respective Conference Series LLC LTD International Journals.

Abstracts will be provided with Digital Object Identifier by

Media partners & Collaborators & Sponsors


Media Partner